Darius Lakdawalla of the University of Southern California discusses the economics of pharmaceutical markets and the impacts of COVID-19 from the manufacturer perspective.
In particular, he discusses innovation and vaccine liability matters, and how pharmaceutical manufacturers might interact with other market stakeholders to address issues raised by COVID-19. In addition, Professor Lakdawalla describes common empirical errors in economic analyses performed for litigation, and the challenges brought on by COVID-19 in this process.
The podcast is available from the Speaking of Health Law channel of the American Health Law Association.
The views expressed herein do not necessarily represent the views of Cornerstone Research.